All In Biotech

Drug Trial Radar · NCT07881887

A Study of LY4167586 in Participants With Obesity or Overweight With or Without Type 2 Diabetes

A Phase 1, Randomized, Participant- and Investigator-Blinded, Placebo-Controlled, Parallel-Design Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Dose Regimens of LY4167586 in Participants With Obesity or Overweight With or Without Type 2 Diabetes

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 617 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

617

Planned (sponsor's estimate)

Start

Oct 22, 2026

Primary completion

Mar 2029

Study completion Mar 2029

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
Oct 20, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to look at how safe and well-tolerated LY4167586 is in participants with obesity or overweight with or without Type 2 Diabetes. Blood tests will be performed to check how much LY4167586 gets into the bloodstream and how long it takes the body to eliminate it following a single administration. Participation in the study will last between approximately 53 to 89 weeks. For each participant (excluding those in Part B), the study will include between 5 and 7 stays in the Clinical Research Unit (CRU), each stay lasting between approximately 8 and 10 nights.

Conditions

  • Obesity
  • Overweight
  • Diabetes Mellitus, Type 2

Interventions

  • LY4167586Drug

    administered SC

  • PlaceboDrug

    administered SC

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationTime frame: Baseline through Study Completion (Estimated as Week 89)

Locations

15 sites in 2 countries. Site status is shown where the registry gives one.

  • Woodland Research Northwest, LLC

    Rogers, Arkansas · Not yet recruiting

  • CenExel ACT

    Anaheim, California · Recruiting

  • Collaborative Neuroscience Network - CNS

    Los Alamitos, California · Recruiting

  • Diablo Clinical Research, Inc.

    Walnut Creek, California · Recruiting

  • Fortrea Clinical Research Unit

    Daytona Beach, Florida · Recruiting

  • Advanced Pharma CR, LLC

    Miami, Florida · Not yet recruiting

  • Clinical Site Partners, LLC DBA CSP Orlando

    Winter Park, Florida · Recruiting

  • Centricity Research

    Columbus, Georgia · Recruiting

  • CenExel iResearch, LLC

    Decatur, Georgia · Recruiting

  • QPS

    Springfield, Missouri · Recruiting

  • CenExel-HRI

    Marlton, New Jersey · Recruiting

  • Ohio Clinical Trials

    Columbus, Ohio · Recruiting

  • Fortrea Clinical Research Unit

    Dallas, Texas · Recruiting

  • Worldwide Clinical Trials, Inc.

    San Antonio, Texas · Recruiting

  • Lilly Centre for Clinical Pharmacology

    Singapore, Singapore · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.